off-the-shelf– tag –
-
UCLA Scientists Mass-Produce Ready-to-Use Cord Blood-Derived T Cells for Solid Tumors in 6 Weeks at $5,000/Dose, Avoiding GvHD Risk
UCLA USA Overview UCLA researchers have developed a platform to mass-produce cancer-fighting T cells from cord blood stem cells, engineered to target solid tumors. This innovative approach generates trillions of therapeutic cells (thousa... -
SCG Cell Therapy Opens Automated Global Manufacturing & R&D Center in Singapore, Targeting 80% Cleanroom Reduction, 10x Production Capacity, and 70% Cost Cuts
Insight, China's Pharmaceutical Industry Singapore Overview SCG Cell Therapy has launched its global manufacturing and R&D center in Singapore, featuring a first-in-class, closed-off automated cell therapy production system. This cut... -
Democratizing Immunotherapy: Tec de Monterrey Pioneers Cost-Effective NK Cell Production Using Autologous Plasma
Facebook (Tec de Monterrey) Mexico Overview A research team at Tec de Monterrey's Toluca campus in Mexico has developed an innovative method to optimize natural killer (NK) cell cultures, utilizing readily available autologous human plas... -
Lineage Cell Therapeutics Secures US Patent for AlloSCOPE™ 5D Platform, Advancing Scalable Allogeneic iPSC Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics has been granted a U.S. Patent for its proprietary AlloSCOPE™ 5D manufacturing platform, designed for high-volume, low-passage, undifferentiated, and genetically stable pluripotent ste... -
AI-Integrated Bioreactors Revolutionize Allogeneic Cell Therapy Manufacturing, Unlocking Scalability and Affordability
sanandres.uep.edu.py Paraguay Overview Allogeneic cell therapy manufacturing is undergoing a significant transformation, driven by the integration of automated, closed-system bioreactors and AI/machine learning for real-time monitoring. ... -
Sana Biotechnology Targets 2026 IND for iPSC-Derived Hypoimmune Pancreatic Islet Cell Therapy SC451 in Type 1 Diabetes
TipRanks / Sana Biotechnology, Inc. USA Overview Sana Biotechnology updated its investor presentation, emphasizing pipeline advancements, particularly for SC451, an iPSC-derived hypoimmune pancreatic islet cell therapy for Type 1 diabete... -
Fate Therapeutics to Present Encore Clinical Data for iPSC-Derived FT819 in Systemic Scleroderma
Fate Therapeutics, Inc. Investors USA Overview Fate Therapeutics will re-present clinical data for FT819, its iPSC-derived, off-the-shelf CAR T-cell product candidate, at the CCR – West 2026 conference. The data potentially shows early c... -
Allogeneic Cell Therapy Manufacturing: Challenges, Advantages, and the Key Role of Automated Bioreactors for Scalability
sdg.azte.co Global Overview This article delves into the complexities of allogeneic cell therapy manufacturing, highlighting its advantages such as scalability, off-the-shelf availability, and cost-effectiveness. The manufacturing proces... -
GentiBio Publishes in EMBO Molecular Medicine, Detailing Technology Enabling Durable Persistence of Allogeneic T-Cell Therapies
GentiBio (Press Release) USA Overview GentiBio announced the publication in EMBO Molecular Medicine of a paper detailing an innovative technology enabling durable in vivo persistence of allogeneic T-cell therapies. This approach addresse... -
Repurposing Photo Paper for Scalable 3D Biosensing Platform: Breakthrough Low-Cost, Label-Free, Time-Resolved Cell Analysis Achieved
ACS Publications USA Overview Researchers developed a scalable 3D biosensing platform by repurposing off-the-shelf photo paper for label-free, time-resolved cell analysis, overcoming limitations of traditional 3D cell culture. This innov...
